A Deep Dive into AI application in medical imaging ‘endless’, yet infrastructure lacking: Innovations and Clinical Prospects

Introduction

In a significant development for the medical technology sector, a new breakthrough has emerged. This article provides an in-depth analysis of the core technology behind # AI application in medical imaging ‘endless’, yet infrastructure lacking, its clinical value, and its potential impact on the future healthcare landscape.

AI application in medical imaging ‘endless’, yet infrastructure lacking

Medical imaging has emerged as a key healthcare domain in which AI is being deployed on the ‘front lines’.

GlobalData analysis forecasts that AI in healthcare will reach a valuation of $19bn by 2027. Image credit: greenbutterfly via Shutterstock.com.

The passage of innovation for artificial intelligence’s (AI) application in medical imaging has “no endpoint”, a CEO has said.

Speaking with Medical Device Network at Life Sciences Baltics 2025, which took place in Vilnius, Lithuania between 16-19 September, DeepLook Medical’s CEO Marissa Fayer stated how AI is set to continue making a big impact on the medical imaging space moving forward.

Fayer outlined that while AI in medical imaging is primarily focused on visualisation and decision support at this time, down the line its use is likely to develop and expand into areas including fully-fledged decision-making, interpretation, and longitudinal forecasting.

“I don’t think there’s an end in sight for AI in the imaging space, especially because we’re dealing with actual images, and so they can be interpreted and they can be read,” Fayer said.

According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a $19bn valuation by 2027.

While Fayer is bullish on the continued fortunes of AI’s application in imaging, she noted that a key challenge lies in how to effectively implement the technology in real time and at scale.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Everyone loves a study, a pilot, a paper, but how do you implement that into real clinical practice? That becomes the challenge. But in my view, if anybody in any industry is going to do it, it’s absolutely going to be in the imaging space first,” Fayer said.

There is clear investor appetite for AI application in medical imaging. Cleerly and RadAI – both companies developing AI solutions for radiology – have raised $106m and $60m respectively in the past year.

Elaborating further, Fayer explained that a current “unwillingness” among some practitioners to want to give up decision control to AI is a delimiting factor of wider adoption in some instances, yet legacy systems are a dominant obstacle.

Fayer explained: “I don’t think the adoption of AI or lack thereof has fundamentally to do with physicians not wanting it. Rather, it’s the hospital systems, especially in the US and in Europe and in the UK – they’re legacy systems, and so it makes it harder to implement different technologies.”With this in mind, Fayer’s observation is that the adoption of AI in healthcare systems is occurring in lower- and middle-income countries given they are less burdened by extensive legacy systems, meaning they can more readily build infrastructure with the technology [AI] in at the outset.

Fayer’s remarks echo those of fellow experts who have already called for upgrades to digital infrastructure for facilitation AI’s adoption in healthcare frameworks.

“I think that as an industry, it is important that we find a way to overcome the legacy systems hurdle, but we also need to remain focused on developing countries, because that’s where AI adoption is going to take off quite extensively,” Fayer concluded.

Conclusion

In summary, this new technology not only represents a remarkable engineering achievement but also opens up new possibilities for treating related conditions. We look forward to its significant role in future clinical practice and will continue to monitor its development.